Clinical Trial Update: Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing ALBIS for protection against gastroduodenal mucosal injury in patients on dual antiplatelet therapy after PCI.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastritis
• Gastroduodenal Ulcer

Drugs mentioned

• Albis

Snippet

Sponsor: Young-Hak Kim, MD, PhD | Conditions: Gastritis, Gastroduodenal Ulcer | Phase 4 | Status: COMPLETED